Posted by Michael Wonder on 18 Feb 2025
Novartis’ Kisqali granted MHRA approval to treat early breast cancer patients
5 February 2025 - The medicine is already approved in the UK to treat advanced cases of the disease.
Novartis’ Kisqali (ribociclib) has been approved by the MHRA to treat a broad population of early breast cancer patients.
